ClinicalTrialsFinder
RecruitingNCT06856161

A Novel Blood Test as a Biomarker in Mental Health

A Novel Blood Test as a Differential Diagnosis and Drug Efficacy Biomarker in Mental Health

Sponsor

Fraser Health

Enrollment

500 participants

Start Date

Mar 25, 2025

Study Type

OBSERVATIONAL

Conditions

Depression - Major Depressive DisorderSubstance Use DisordersAlcohol Use DisorderAlcohol ConsumptionPsychosisAnxiety Disorder (Panic Disorder or GAD)Schizophenia DisorderMania (Neurotic)

Summary

This longitudinal, observational study aims to assess whether the characteristics of a novel blood peripheral biomarker can serve as indicators for depression and schizophrenia in patients at the Royal Columbian Hospital Psychiatric Clinics. The study will evaluate whether changes in these biomarker characteristics can help distinguish between depressed patients who do or do not respond to treatment and between individuals experiencing a single psychotic episode and those at risk of progressing to schizophrenia. To achieve this, blood samples and standardized mental health assessments will be collected across three study visits from up to 500 participants, grouped into two study arms based on their diagnosis: Depression (DEP) or Psychosis/Schizophrenia (PSY).

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating a new blood test to see if it can serve as a reliable biological marker (biomarker) for mental health conditions like depression and psychosis, potentially helping doctors track and diagnose these conditions more objectively. **You may be eligible if...** - You are 19 years or older - You have suspected, new, or established depression OR a first episode of psychosis or suspected/established schizophrenia - You are able to complete mental health questionnaires at study visits **You may NOT be eligible if...** - You are unable to give informed consent - You are currently in another research study involving drugs or devices that could affect mental health treatment - You are currently on extended leave under British Columbia's Mental Health Act Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Royal Columbian Hospital

New Westminster, British Columbia, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06856161

Related Trials

Human Laboratory Study of Apremilast for Alcohol Use Disorder

NCT073252663 locations

Semaglutide Therapy for Alcohol Reduction (STAR)

NCT060158931 location

Environment and Alcohol: A Pilot Study

NCT068606071 location

NIAAA Natural History Protocol

NCT022318401 location

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT0679339767 locations